Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abivertinib vs Gefitinib in First-line Advanced EGFR-mutated NSCLC
NCT03856697Phase 3Unknown
- Sponsor
- ACEA Therapeutics
- Start
- Mar 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abivertinib in non-small cell lung cancer (NSCLC), sponsored by ACEA Therapeutics. Status: unknown.
02
Drugs
abivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03856697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856697.